214 related articles for article (PubMed ID: 12107236)
1. The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults.
Nielsen S; Møller N; Pedersen SB; Christiansen JS; Jørgensen JO
J Clin Endocrinol Metab; 2002 Jul; 87(7):3274-8. PubMed ID: 12107236
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of lipolysis during acute GH exposure increases insulin sensitivity in previously untreated GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
Eur J Endocrinol; 2003 Dec; 149(6):511-9. PubMed ID: 14640991
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Nielsen S; Møller N; Christiansen JS; Jørgensen JO
Diabetes; 2001 Oct; 50(10):2301-8. PubMed ID: 11574412
[TBL] [Abstract][Full Text] [Related]
4. Restoration of growth hormone (GH) response to GH-releasing hormone in elderly and obese subjects by acute pharmacological reduction of plasma free fatty acids.
Pontiroli AE; Manzoni MF; Malighetti ME; Lanzi R
J Clin Endocrinol Metab; 1996 Nov; 81(11):3998-4001. PubMed ID: 8923850
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of the rise in FFA by Acipimox partially prevents GH-induced insulin resistance in GH-deficient adults.
Segerlantz M; Bramnert M; Manhem P; Laurila E; Groop LC
J Clin Endocrinol Metab; 2001 Dec; 86(12):5813-8. PubMed ID: 11739444
[TBL] [Abstract][Full Text] [Related]
6. Effects of lowering circulating free fatty acid levels on protein metabolism in adult growth hormone deficient patients.
Nielsen S; Jørgensen JO; Hartmund T; Nørrelund H; Nair KS; Christiansen JS; Møller N
Growth Horm IGF Res; 2002 Dec; 12(6):425-33. PubMed ID: 12423628
[TBL] [Abstract][Full Text] [Related]
7. Effects of GH replacement therapy in adults on serum levels of leptin and ghrelin: the role of lipolysis.
Vestergaard ET; Hansen TK; Nielsen S; Moller N; Christiansen JS; Jorgensen JO
Eur J Endocrinol; 2005 Oct; 153(4):545-9. PubMed ID: 16189176
[TBL] [Abstract][Full Text] [Related]
8. The decisive role of free fatty acids for protein conservation during fasting in humans with and without growth hormone.
Nørrelund H; Nair KS; Nielsen S; Frystyk J; Ivarsen P; Jørgensen JO; Christiansen JS; Møller N
J Clin Endocrinol Metab; 2003 Sep; 88(9):4371-8. PubMed ID: 12970312
[TBL] [Abstract][Full Text] [Related]
9. Kinetics and utilization of lipid sources during acute exercise and acipimox.
Nellemann B; Søndergaard E; Jensen J; Pedersen SB; Jessen N; Jørgensen JO; Nielsen S
Am J Physiol Endocrinol Metab; 2014 Jul; 307(2):E199-208. PubMed ID: 24895285
[TBL] [Abstract][Full Text] [Related]
10. Continuation of growth hormone (GH) substitution during fasting in GH-deficient patients decreases urea excretion and conserves protein synthesis.
Nørrelund H; Møller N; Nair KS; Christiansen JS; Jørgensen JO
J Clin Endocrinol Metab; 2001 Jul; 86(7):3120-9. PubMed ID: 11443176
[TBL] [Abstract][Full Text] [Related]
11. Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections.
Amato G; Mazziotti G; Di Somma C; Lalli E; De Felice G; Conte M; Rotondi M; Pietrosante M; Lombardi G; Bellastella A; Carella C; Colao A
J Clin Endocrinol Metab; 2000 Oct; 85(10):3720-5. PubMed ID: 11061530
[TBL] [Abstract][Full Text] [Related]
12. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe GH deficiency at completion of linear growth.
Carroll PV; Drake WM; Maher KT; Metcalfe K; Shaw NJ; Dunger DB; Cheetham TD; Camacho-Hübner C; Savage MO; Monson JP
J Clin Endocrinol Metab; 2004 Aug; 89(8):3890-5. PubMed ID: 15292323
[TBL] [Abstract][Full Text] [Related]
13. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
Laursen T; Gravholt CH; Heickendorff L; Drustrup J; Kappelgaard AM; Jørgensen JO; Christiansen JS
J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
[TBL] [Abstract][Full Text] [Related]
15. The control on growth hormone release by free fatty acids is maintained in acromegaly.
Lanzi R; Losa M; Mignogna G; Caumo A; Pontiroli AE
J Clin Endocrinol Metab; 1999 Apr; 84(4):1234-8. PubMed ID: 10199760
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of lipolysis stimulates whole body glucose production and disposal in normal postabsorptive subjects.
Fery F; Plat L; Baleriaux M; Balasse EO
J Clin Endocrinol Metab; 1997 Mar; 82(3):825-30. PubMed ID: 9062490
[TBL] [Abstract][Full Text] [Related]
17. Effect of growth hormone (GH) on glycerol and free fatty acid metabolism during exhaustive exercise in GH-deficient adults.
Gibney J; Healy ML; Stolinski M; Bowes SB; Pentecost C; Breen L; McMillan C; Russell-Jones DL; Sonksen PH; Umpleby AM
J Clin Endocrinol Metab; 2003 Apr; 88(4):1792-7. PubMed ID: 12679475
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.
Bramnert M; Segerlantz M; Laurila E; Daugaard JR; Manhem P; Groop L
J Clin Endocrinol Metab; 2003 Apr; 88(4):1455-63. PubMed ID: 12679422
[TBL] [Abstract][Full Text] [Related]
19. Short- and long-term effects of growth hormone (GH) replacement on protein metabolism in GH-deficient adults.
Shi J; Sekhar RV; Balasubramanyam A; Ellis K; Reeds PJ; Jahoor F; Sharma MD
J Clin Endocrinol Metab; 2003 Dec; 88(12):5827-33. PubMed ID: 14671176
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone-induced insulin resistance is associated with increased intramyocellular triglyceride content but unaltered VLDL-triglyceride kinetics.
Krag MB; Gormsen LC; Guo Z; Christiansen JS; Jensen MD; Nielsen S; Jørgensen JO
Am J Physiol Endocrinol Metab; 2007 Mar; 292(3):E920-7. PubMed ID: 17132823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
